Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Oryzon Genomics, S.A.
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
March 25, 2026
ORYZON Announces U.S. Patent Grant Covering Iadademstat Combinations with Venetoclax
March 23, 2026
ORYZON Receives European Medicines Agency Approval to Initiate a Phase II Study of iadademstat in Essential Thrombocythemia
February 24, 2026
ORYZON to Participate in Upcoming Events in February and March
February 19, 2026
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
February 13, 2026
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in Extensive Stage Small Cell Lung Cancer
February 12, 2026
ORYZON Strengthens Patent Portfolio for Vafidemstat With New Decision to Grant in Japan
February 11, 2026
←
Previous Page
1
2